Table 1. Clinical characteristics of patients.
| Characteristic | Weekly cisplatin (n = 73) | Cisplatin every three weeks (n = 81) | P * |
| Age (years) | .351 | ||
| ≤50 | 52 | 63 | |
| >50 | 21 | 18 | |
| ≤18 | 0 | 3 | .247 |
| >18 | 73 | 78 | |
| Sex | .581 | ||
| Male | 56 | 59 | |
| Female | 17 | 22 | |
| Histology | .116 | ||
| WHO I | 1 | 0 | |
| WHO II | 7 | 3 | |
| WHO III | 65 | 75 | |
| BSCC | 0 | 3 | |
| T classification† | .651 | ||
| T1 | 7 | 13 | |
| T2 | 17 | 17 | |
| T3 | 31 | 30 | |
| T4 | 18 | 21 | |
| N classification† | .538 | ||
| N0 | 14 | 13 | |
| N1 | 42 | 55 | |
| N2 | 12 | 8 | |
| N3 | 5 | 5 | |
| Staging† | .939 | ||
| II | 18 | 22 | |
| III | 33 | 33 | |
| IVA | 17 | 21 | |
| IVB | 5 | 5 | |
| OTT (days) | .554 | ||
| Median | 43 | 44 | |
| SD | 4.3 | 4.0 | |
| Response rate | .258 | ||
| CR | 60 | 61 | |
| PR | 11 | 19 |
WHO: World Health Organization; BSCC: basaloid squamous cell carcinoma; CR: complete response; PR: partial response; SD: standard deviation; OTT: overall treatment time.
*P-values were calculated using the chi-square test (or Fisher's exact test) and Mann–Whitney U test.
†
According to the 7th AJCC/International Union against Cancer staging system.